Inokuchi T, et al. - Researchers conducted this multicenter, retrospective study to analyze the long-term outcomes of patients with Crohn's disease (CD) who received infliximab (IFX) or adalimumab (ADA) as the first-line biologics. Disease courses were evaluated in patients with biological-naïve CD who were initiated on IFX or ADA treatment, even after initial biologics loss of response (LOR). A total of 263 patients with CD were eligible for analysis, 183 were first treated with IFX, and 80 were first treated with ADA. It was noted that the median observation period was 64.2 months. The authors concluded that there was no significant difference in the long-term prognosis between biological-naïve CD patients who first began IFX and ADA treatment. Firstly, patients treated with IFX were likely to discontinue the agent due to adverse events, while first patients treated with ADA were likely to discontinue due to failure of treatment or LOR.